Literature DB >> 15370024

Non-injecting routes of administration among entrants to three treatment modalities for heroin dependence.

Shane Darke1, Kate Hetherington, Joanne Ross, Michael Lynskey, Maree Teesson.   

Abstract

A sample of 535 entrants to opioid dependence treatments across three treatment modalities were administered a structured interview to ascertain the prevalence of non-injecting heroin use. Ten per cent of participants had used heroin primarily by smoking/inhaling in the month preceding interview, and 9% had used heroin and other drugs exclusively by non-injecting routes. Non-injectors were younger (25.3 vs. 29.5 years), had higher levels of education (10.6 vs. 10.0 years), were more likely to be employed (33 vs. 18%) and had lower levels of recent crime (31 vs. 56%). They also had shorter heroin using careers (5.1 vs. 9.9 years), fewer symptoms of dependence (5.1 vs. 5.6), had been enrolled in fewer previous treatment episodes (3.3 vs. 11.5) and had less extensive lifetime (8.0 vs. 9.1 drug classes) and recent (3.6 vs. 4.9) polydrug use. Non-injectors were substantially less likely to report lifetime (13% vs. 58%) or recent (2% vs. 29%) heroin overdoses. There were no differences between the general physical and psychological health of the two groups. While non-injectors had a lower level of post-traumatic stress disorder (29% vs. 34%), there were no differences in levels of major depression, attempted suicide, antisocial personality disorder, or borderline personality disorder. A substantial minority of Australian treatment entrants are now using heroin exclusively by non-injecting routes. While this group is younger, and has substantially reduced risk of overdose and blood borne virus transmission, the physical and psychological health of non-injectors mirrors that of injectors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15370024     DOI: 10.1080/095952304100017044163

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  7 in total

1.  Prevalence and correlates of opiate overdose among young injection drug users in a large U.S. city.

Authors:  Susan G Sherman; Yingkai Cheng; Alexander H Kral
Journal:  Drug Alcohol Depend       Date:  2006-11-15       Impact factor: 4.492

2.  Estimating the prevalence of injection drug use among black and white adults in large U.S. metropolitan areas over time (1992--2002): estimation methods and prevalence trends.

Authors:  Hannah L F Cooper; Joanne E Brady; Samuel R Friedman; Barbara Tempalski; Karla Gostnell; Peter L Flom
Journal:  J Urban Health       Date:  2008-08-16       Impact factor: 3.671

3.  Factors associated with history of non-fatal overdose among young nonmedical users of prescription drugs.

Authors:  Karol Silva; Sheree M Schrager; Aleksandar Kecojevic; Stephen E Lankenau
Journal:  Drug Alcohol Depend       Date:  2012-09-10       Impact factor: 4.492

Review 4.  Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review.

Authors:  Jonathan Feelemyer; Don Des Jarlais; Kamyar Arasteh; Abu S Abdul-Quader; Holly Hagan
Journal:  Addiction       Date:  2013-08-15       Impact factor: 6.526

5.  Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder.

Authors:  Amanda B Namchuk; Irwin Lucki; Caroline A Browne
Journal:  Adv Drug Alcohol Res       Date:  2022-02-21

6.  Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).

Authors:  Jennifer S Potter; Elise N Marino; Maureen P Hillhouse; Suzanne Nielsen; Katharina Wiest; Catherine P Canamar; Judith A Martin; Alfonso Ang; Rachael Baker; Andrew J Saxon; Walter Ling
Journal:  J Stud Alcohol Drugs       Date:  2013-07       Impact factor: 2.582

7.  Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder.

Authors:  Anna Beth Parlier-Ahmad; Mickeal Pugh; Caitlin E Martin
Journal:  J Racial Ethn Health Disparities       Date:  2021-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.